Brussels Buys Medtech Makers 16 More Months on AI

European Commission pushes AI medical device compliance from August 2026 to December 2027, giving medtech makers 16 extra months.

24 Jul 2026

European medical device makers have gained additional time to prepare for the European Union’s high-risk artificial intelligence rules, after lawmakers revised the AI Act’s implementation schedule through the Digital Omnibus package. Under the new timetable, requirements for high-risk AI systems embedded in products covered by European safety legislation will apply from Aug. 2, 2028. Stand-alone high-risk systems covered separately by the law face an earlier deadline of Dec. 2, 2027.

The distinction is important for the medical technology industry. Under the AI Act, certain AI systems that are products themselves or safety components of regulated products can qualify as high risk when they fall under legislation listed in Annex I. European regulatory guidance treats these product-based systems separately from high-risk uses listed in Annex III, which include areas such as employment, education and access to essential services.

For manufacturers of qualifying AI-enabled medical devices, the later deadline provides more time to coordinate AI Act requirements with existing product regulation and conformity assessments. Industry specialists have pointed to uncertainty over how the AI Act interacts with the European Union’s medical device framework, particularly as technical standards and implementation guidance continue to develop.

Yet the revised timetable does not amount to a broad postponement of the AI Act. Transparency requirements and other provisions remain scheduled to apply from Aug. 2, 2026, while stand-alone high-risk systems move to December 2027. The Council of the European Union said the changes were intended to establish a fixed schedule for delayed high-risk requirements while simplifying implementation.

For the medtech sector, the adjustment shifts the immediate focus from meeting an August 2026 high-risk deadline to preparing for a longer compliance process alongside existing medical device obligations. The additional runway may give manufacturers and regulators more time to align technical documentation, risk management and conformity procedures with the AI rules. How effectively those systems are integrated could shape the European market for AI-enabled medical devices in the years ahead.